Stockwinners Market Radar for January 31, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST Cathie Wood's ARK Investment bought 1.1M shares of Invitae today

18:58 EST Marin Software announces new integration with Yahoo - Marin Software announced a new integration with Yahoo to enable enhanced campaign buying and optimization for advertisers. Through the integration, brands can now include Yahoo DSP campaigns within the MarinOne Platform, making the management, measurement and optimization of holistic, omnichannel campaigns easier than ever. Yahoo DSP puts the power of programmatic advertising in the hands of advertisers, giving them access to premium inventory across the industry's top publishers, ad exchanges and SSPs - including the Yahoo SSP. This comprehensive access allows brands to understand and reach their audiences across multiple dimensions on every device. Advertisers can choose from various formats including video, mobile, desktop, connectedTV, digital out-of-home, and cutting-edge immersive experiences. "We are excited to renew our partnership with Yahoo and continue providing our customers with best-in-class advertising solutions that enable them to reach their target audiences more efficiently and effectively than ever before," said Chris Lien, CEO of Marin Software. "Our goal is always to provide brands and their agencies with industry-leading technology to manage and optimize their digital marketing programs in a single platform, and give them a competitive edge in today's digital marketplace. Working closely with Yahoo we will be able to jointly develop even more innovative products that deliver on this goal."

18:31 EST Mesoblast resubmits BLA to FDA for remestemcel-L - Mesoblast Limited announced it has resubmitted to the U.S. Food and Drug Administration its Biologics License Application for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease. Survival outcomes have not improved over the past two decades for the most severe forms of SR-aGVHD, a life-threatening complication of an allogeneic bone marrow transplant following treatment for blood cancers and other conditions.1-3 The lack of any approved treatments for children under 12 means that there is an urgent need for a therapy that improves the dismal survival outcomes. If remestemcel-L receives FDA approval, it will be the first allogeneic "off-the-shelf" cellular medicine to be approved in the United States, and the first therapy for children under 12 years old with SR-aGVHD. The resubmission contains substantial new information as required by FDA in the Complete Response Letter received in September 2020 to the BLA for remestemcel-L. Mesoblast has maintained an active dialogue with FDA since receiving the CRL and in October 2022 provided a high-level synopsis of the substantial new information under its Investigational New Drug application for remestemcel-L. FDA granted remestemcel-L Fast Track designation, a process to facilitate the development and expedited review of therapies for serious conditions that fill unmet medical needs, and Priority Review designation, which is given to drugs that treat a serious condition and provide a significant improvement in safety or effectiveness over existing treatments. The BLA resubmission will have a review period up to six months from filing upon acceptance by FDA.

18:25 EST General Motors CEO: Couldn't be more excited about EV launches this year - In an interview on CNBC's Mad Money, Mary Barra said GM expects to have nine EV products in the market in 2023. "When we look at some of the challenges this year, we're well positioned," she noted. She expects GM's partnership with LAC will help support up to 1M EVs per year. "There's a lot of unknown in pricing, but we believe we're priced right," she added. People think of GM as an old company, but it has tremendous growth opportunity, Barra said. "We are positioned to help mainstream America make the EV transition by 2035."

18:09 EST Tempur Sealy CFO sells $2.0M in common stock - In a regulatory filing, Tempur Sealy disclosed that its CFO Bhaskar Rao sold 50K shares of common stock on January 27th in a total transaction size of $2.0M.

18:03 EST HostPapa to buy Deluxe's web hosting, logo design operations - Deluxe "announced that it has sold the remainder of its web hosting and logo design businesses to HostPapa. The transaction is expected to close in the first quarter. This transaction follows last year's sale of Deluxe's Australian Hostopia business to Newfold Digital and represents a complete exit from the web hosting and logo design market. Deluxe web hosting and logo design employees will transition to become employees of HostPapa as of the closing. Terms of the sale were not disclosed."

17:30 EST Chembio Diagnostics trading resumes

17:20 EST General Dynamics awarded $481.58M Army contract - General Dynamics was awarded a $481.58M hybrid contract for sustainment of Prophet Enhanced detecting systems. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of Jan. 31, 2028. U.S. Army Contracting Command is the contracting activity.

17:17 EST Electronic Arts sees mid-single digit growth in net bookings in 2024

17:15 EST BAE Systems awarded $651.59M Air Force contract modification - BAE Systems has been awarded a $651.59M fixed-price level of effort contract modification to a previously awarded contract for sustaining engineering services. This contract provides for services support for both the Minuteman III and Sentinel Systems Directorates to ensure the integration of current and future hardware, software, testing, and modifications with the Intercontinental Ballistic Missile Weapon Systems. Work is expected to be completed by January 31, 2025. FY23 operation and maintenance funds; research and development funds; and production funds will be obligated with the associated modification. The Air Force Nuclear Weapon Center is the contracting activity.

17:02 EST Healthcare Realty Trust completes $112.M in asset sales to fund special dividend - Healthcare Realty Trust announced the completion of $112.5M of asset sales in January for net proceeds of $102.8M after accounting for HR's joint venture interest. Since July , the company has generated net proceeds of $1.13B from asset sales and joint venture transactions. These proceeds fully complete the funding of the merger-related special dividend that was paid in July.

17:01 EST Biosynex to acquire Chembio for 45c per share - Biosynex and Chembio Diagnostics announced that the companies have entered into a definitive merger agreement under which Biosynex, through a subsidiary, will acquire Chembio for $0.45 per share, representing a premium of 27% compared to the closing price of Chembio stock on January 30, 2023, in an all-cash transaction valued at $17.2 million. The acquisition combines two leading rapid diagnostic test companies. Each company specializes in the development, manufacturing and marketing of point-of-care diagnostic tests for the professional and at home markets. Chembio, based in the United States, focuses on infectious disease assays covering sexually transmitted infections, respiratory viruses and fever and tropical disease, built on the DPP, SURE CHECK and STAT-PAK proprietary, accurate and easy-to-use technology platforms. Biosynex, based in France, provides pharmacies and professional healthcare settings with a diversified portfolio of rapid tests covering different market segments including infectious disease and women's health tests, Point of Care devices and molecular diagnostics systems. Biosynex will operate Chembio and its 100% owned German, Brazil and Malaysia subsidiaries as a wholly owned group. "The acquisition of Chembio significantly advances our mission to develop, manufacture and market rapid diagnostics for screening, diagnosis and prevention to facilitate patient care and monitor health," said Larry Abensur, Chief Executive Officer of Biosynex. "Chembio's portfolio of diagnostic solutions and technology platforms complement our current test portfolio. DPP, SURE CHECK and STAT-PAK are clinically validated with accurate results, ease-of-use, and U.S. FDA and global regulatory approvals including CE marked and WHO prequalified products to provide transformative commercial opportunities that can represent meaningful growth drivers over the near and long-term. Additionally, there are numerous strong synergies across our businesses that can be leveraged to create significant cost savings as a scaled organization. We are excited to enhance our position as key European player for professional point-of-care and self-test diagnostics." Transaction Details Under the terms of the merger agreement, Biosynex, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Chembio. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Chembio's outstanding shares and other customary conditions. Upon the successful completion of the tender offer, Biosynex's acquisition subsidiary will be merged into Chembio, and any remaining shares of common stock of Chembio will be canceled and converted into the right to receive the same $0.45 per share price payable in the tender offer. The transaction is expected to close in the first quarter of 2023. The terms of the merger agreement were unanimously approved by the Boards of Directors of both companies, and the Board of Directors of Chembio intends to recommend the transaction to Chembio's stockholders.

16:58 EST Triumph Financial director buys $2.56M in common stock - In a regulatory filing, Triumph Financial disclosed that its director Carlos Sepulveda bought 47K shares of common stock on January 30th in a total transaction size of $2.56M.

16:56 EST Snap expects to see full benefit of cost reductions in Q1 - "We are on track to realize the full $500 million in cost reductions we committed to deliver as part of our strategic reprioritization by Q1 2023. The vast majority of the cost reductions initiatives have now been implemented. However, we continued to wind down certain operations throughout Q4, so we will see the full benefit of the cost reductions in Q1 as expected."

16:48 EST Snap sees Q1 DAU 382M-384M, expects adjusted EBITDA breakeven in Q1 - "As we look forward to Q1, we expect to continue to deliver strong growth in our global community and, as a result, we anticipate DAU will be between 382 and 384 million in Q1 2023. On the monetization side, we anticipate that the operating environment will remain challenging, as we expect the headwinds we have faced over the past year to persist throughout Q1. In addition, we expect to introduce a number of new improvements and optimizations to our DR platform that we believe will drive improvement for our partners and our business over time, but that may be disruptive to auction dynamics in the near term, especially given the weak demand environment, as discussed in more detail above. As a result, we've observed a year-over-year decline in revenue of approximately 7% quarter-to-date. Our internal forecast assumes revenue will be between -10% to -2% year-over year in Q1. Given the work we have completed to reprioritize our cash cost structure, we believe we have a path to adjusted EBITDA breakeven in Q1."

16:46 EST Snap says the quarter 'materialized largely as expected' - "Q4 revenue was $1.3 billion, flat year-over-year and up 2% year over-year on a constant currency basis. The quarter materialized largely as expected, with weaker demand from our brand oriented advertising business, which declined 11% year-over-year, while our DR business performed relatively better, up 4% year over-year. Weaker demand for brand-oriented advertising was most apparent in the period between Thanksgiving and the end of Q4, where we have historically observed peak demand for brand advertising products."

16:37 EST Transcode: TTX-RIGA preclinical proof-of-mechanism study in melnoma 'successful' - TransCode Therapeutics reported "successful" preclinical proof-of-mechanism studies with its immunotherapy candidate, TTX-RIGA, in melanoma, said Transcode Therapeutics in a statement. TTX-RIGA, a novel immunotherapeutic candidate for the treatment of cancer, is designed to work by binding to an intracellular receptor called RIG-I . This is expected to result in targeted activation of innate immunity in the tumor microenvironment. Recent developments in the use of pattern recognition receptors or PRRs such as RIG-I aim to harness the innate power of the immune system for cancer therapy. TransCode believes that understanding how to recruit PRRs, such as RIG-I, in a tumor-selective manner is critical for its adoption in the clinic. TransCode seeks to address this challenge by developing a strategy for tumor-selective activation of an immune response specific to cancer cells using systemic administration with its proprietary nanoparticle delivery system, TTX. TransCode anticipates that Immune activation will not be triggered in healthy tissues that do not express the target, but rather will be selectively activated in tumors and metastases that do express the target.

16:34 EST Pan American Silver's shareholders approve arrangement with Yamana and Agnico - Pan American Silver announced that at its special meeting of shareholders held earlier today, shareholders of Pan American overwhelmingly approved the resolution to authorize the issuance of up to 156,923,287 common shares of Pan American in respect of the arrangement involving Pan American, Agnico Eagle Mines Limited and Yamana Gold under the Canada Business Corporations Act. In addition to the approval by Pan American Shareholders, shareholders of Yamana approved the Arrangement at the special meeting of Yamana Shareholders held today. The Arrangement is expected to be completed within the Q1, subject to approval by the Ontario Superior Court of Justice, approval from the Mexican Federal Economic Competition Commission and satisfaction or waiver of certain other closing conditions.

16:33 EST Transocean announces $392M contract award for ultra-deepwater drillship - Transocean announced that the ultra-deepwater drillship, Dhirubhai Deepwater KG2, has been awarded a 910-day contract by a national oil company for work offshore Brazil. The estimated backlog of $392M excludes a mobilization fee of 90 times the contract dayrate. The new contract is expected to commence in the third quarter of 2023.

16:31 EST Casey's General Stores says Q3 SSS to date in lower half of annual target range - The company states: "Third quarter to date performance remains consistent with our expectations for the full year. Specifically, same-store inside sales for the quarter are in the lower half of our annual range of a 5-7% increase. Same-store fuel gallons for the quarter are near the low end of the annual range of a flat to 2% increase. Third quarter to date fuel margins are similar to our reported second quarter fuel margins. Excluding the non-recurring item below, total operating expense growth is expected to be near the low end of the annual range of a 9-10% increase. During the quarter the company received an approximately $15 million one-time payment from the resolution of certain legal matters. These proceeds will be recorded as a reduction to operating expense in the quarter and they were not included in the previous operating expense guidance for the third quarter or the fiscal year."

16:30 EST Super Micro Computer reports Q2 gross margin 18.8% vs. 14.0% y/y

16:28 EST LumiraDx receives noncompliance notification from Nasdaq - LumiraDx announced that it has received notification from Nasdaq that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on Nasdaq, since the closing bid price for the company's common shares on Nasdaq was below $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5450 requires the common shares to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810 provided that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days.

16:21 EST Hawaiian Holdings sees Q1 ASMs up 14%-17% - Sees Q1 RASM up 7.5%-10.5%; CASM ex-fuel, non recurring items down 1% to up 2%.

16:19 EST Juniper CFO says aiming to expand 2023 operating margin by at least 100bps - CFO Ken Miller states: "In addition to record revenue results, we achieved strong profitability during the December quarter, as non-GAAP gross and operating margin both exceeded the mid-point of our forecast and enabled us to beat the mid-point of our non-GAAP EPS outlook. We remain focused on delivering profitable growth and are confident in our ability to expand our non-GAAP operating margin by at least 100 basis points in 2023."

16:13 EST Snap falls 14% to $9.96 per share after Q4 results

16:11 EST Snap reports Q4 DAUs up 17% y/y to 375M - The company states: "DAUs were 375 million in Q4 2022, an increase of 56 million, or 17% year-over-year. DAUs increased sequentially and year-over-year in each of North America, Europe, and Rest of World. Total time spent watching Spotlight content grew over 100% year-over-year. 17 content partners reached over 50 million global viewers each in Q4 2022."

16:10 EST Valero raises quarterly dividend to $1.02 per share from 98c - The Board of Directors of Valero Energy Corporation has approved an increase in the company's regular quarterly cash dividend on common stock from 98c per share to $1.02 per share. The dividend is payable on March 16, 2023 to holders of record at the close of business on February 14, 2023. The increase in the dividend raises the annualized cash dividend rate on Valero's common stock to $4.08 per share.

16:09 EST Rockwell Automation names Bob Buttermore SVP, chief supply chain officer - Rockwell Automation announced that Robert "Bob" Buttermore will be named senior vice president and Chief Supply Chain Officer, effective Feb. 13. He will report to Rockwell Chairman and CEO Blake Moret. In this role, Buttermore heads the Integrated Supply Chain organization and is responsible for leading global strategy and development of Manufacturing Operations, Manufacturing Engineering, Quality, Sourcing, Logistics, and Customer Care. Buttermore succeeds Brad Skogman, who has served as the interim head of ISC since June 2022.

16:09 EST Rallybio names Jonathan Lieber CFO - Rallybio Corporation announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer, effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023.

16:07 EST Old Dominion names Kevin Freeman to succeed Greg Gantt as president, CEO - Old Dominion Freight Line announced that effective July 1, 2023, its Board of Directors has elected Kevin M. Freeman to succeed Greg C. Gantt as the Company's President and Chief Executive Officer. Mr. Gantt will retire from the Company effective June 30, 2023, but expects to remain a member of the Company's Board of Directors. Mr. Freeman, who has served as the Company's Executive Vice President and Chief Operating Officer since May 2018, joined the Company in February 1992 and has assumed ever-increasing roles and responsibilities over the past 30 years. David S. Congdon, the Company's Executive Chairman of the Board, said, "On behalf of our Board of Directors and the entire Company, I want to thank Greg for his leadership and his numerous contributions and accomplishments at Old Dominion. Greg has been a visionary leader and a steward of the Company's unique culture. He was also directly responsible for developing our best-in-class service offering, where every employee is focused on providing our customers with superior service at a fair price. This value proposition has supported our ability to win market share for many years, and we believe our continued focus on this core principle will support our ongoing ability to grow. I am excited about Greg's opportunity to continue to serve on our Board of Directors and look forward to his continued contributions to Old Dominion's success."

16:06 EST Western Digital enters $900M convertible preferred equity investment by Apollo - Western Digital "announced that funds managed by affiliates of Apollo Global Management, Inc. led the purchase of $900 million of convertible preferred stock of Western Digital, along with Elliott Investment Management L.P. who also invested in the convertible offering. The investment strengthens Western Digital's financial position and flexibility as the company continues its review of strategic alternatives aimed at further optimizing long-term value for its shareholders. The preferred stock has an initial conversion price of $47.75 per share of Western Digital's stock, subject to customary anti-dilution and other adjustments. The initial conversion price of $47.75 represents a 25% premium to the volume-weighted average closing price of the common stock over the 20-day period ending on January 30, 2023, and a 44% premium to the closing price on January 4, 2023, the last trading day prior to merger rumors involving Western Digital. The preferred stock will bear a cumulative and compounding dividend at a rate of 6.25% per annum over the initial liquidation preference of $1,000.00, until the seven-year anniversary of the closing, at which time the dividend shall increase to 7.25% per annum until the ten-year anniversary of the closing, at which time the dividend shall increase to 8.25% per annum."

16:04 EST Electronic Arts delays 'Star Wars Jedi: Survivor' launch to April 28 - EA announced a new release date for Star Wars Jedi: Survivor, which will launch globally on April 28th.

16:03 EST Amgen sees FY23 CapEx about $925M - FY23 share repurchases not to exceed $500M.

16:00 EST Dragoneer Growth Opportunities trading resumes

15:51 EST Cvent jumps 15% after WSJ says company exploring sale

14:58 EST Northern Dynasty says EPA action 'unlawful,' likely to take legal action - Northern Dynasty Minerals and its 100%-owned U.S.-based subsidiary Pebble Limited Partnership responded to today's announcement by the Environmental Protection Agency of its issuance of a Final Determination, which is consistent with the Proposed Determination released in early December, 2022, with the following statement by John Shively, CEO of PLP: "Today's action by the EPA to preemptively veto the proposed Pebble Project is unlawful and unprecedented. For well over a decade, we have argued that fair treatment under the rules and regulations of the U.S should be followed for Pebble or any other development project. Unfortunately, the Biden EPA continues to ignore fair and due process in favor of politics. This preemptive action against Pebble is not supported legally, technically, or environmentally. As such, the next step will likely be to take legal action to fight this injustice."

14:24 EST BlackRock reports 7.2% passive stake in Silvergate Capital - BlackRock (BLK) disclosed it holds a 7.2% stake in Silvergate Capital (SI), or 2,285,197 shares. The filing indicates the stake is passive.

13:41 EST ContextLogic to reduce workforce by roughly 17% - According to a regulatory filing, on January 31, 2023, ContextLogic announced a plan to reduce its workforce by up to 150 employees, representing approximately 17% of the company's current global workforce. The Plan is intended to refocus the company's operations to support its ongoing business prioritization efforts, better align resources, and improve operational efficiencies. The company estimates that it will incur non-recurring charges of approximately $3M to $4M in connection with the Plan, primarily related to employee severance and other personnel reduction costs. The company expects that the majority of these charges will be incurred in the first quarter of 2023 and that the implementation of the Plan will be substantially complete by the end of the second quarter of 2023. The company expects to realize run-rate savings of approximately $14M to $23M on an annualized basis starting in the third quarter of 2023.

13:19 EST Green Plains spikes over 10% after investor Ancora urges 'full sale' - Shares of ethanol maker and distributor Green Plains are up over 11% to $34.50 per share, on Tuesday afternoon after Ancora Holdings Group, which owns nearly 7% of the company's outstanding common shares, said in a letter to the company's Board of Directors, "We do, however, believe the best path to delivering shareholders an optimal risk-adjusted return is by pursuing a full sale of the Company given the meaningful risks we have identified and the considerable demand for renewable assets by well-funded buyers."

12:49 EST Amazon Publisher Direct, Paramount Advertising announce expanded agreement - Amazon Publisher Direct (AMZN) and Paramount Advertising (PARA) announced that they have expanded their agreement, providing Amazon Ads customers with direct programmatic access to more of Paramount Global's streaming TV content. "This includes enabling increased advertiser reach both across devices and in new, international locales. Advertisers using Amazon DSP can programmatically reach exclusive Amazon audiences across EyeQ, Paramount Global's premium video advertising platform, which includes the company's ad-supported streaming services Pluto TV and Paramount+, as well as leading brands such as CBS News, CBS Sports HQ, Comedy Central, MTV, VH1, Paramount Network, BET, and ET Live. Enabling direct access to more Paramount Global content makes it even easier for Amazon advertisers to engage their desired audience via streaming TV, while leveraging a streamlined supply path to EyeQ inventory. Driven by free streaming television service Pluto TV, Amazon Publisher Direct and Paramount Global are also helping optimize programmatic access for advertisers at scale internationally, expanding beyond the United States into additional locales, such as the United Kingdom and Germany," Amazon stated in a blog post. Reference Link

12:18 EST Atlas Technical Consultants acquired by GI Partners for $12.25 per share - Atlas Technical Consultants announced earlier today that it has entered into a definitive agreement to be acquired by private investment firm GI Partners in an all-cash transaction valued at approximately $1.05B, including outstanding debt. Under the terms of the transaction, Atlas shareholders will receive $12.25 per share in cash, which represents a premium of approximately 124% over the Company's unaffected closing share price of $5.47 on January 30. The transaction was unanimously approved by Atlas' board, which recommends that Atlas shareholders vote in favor of the transaction. Affiliates of Bernhard Capital Partners, which own approximately 43% of the outstanding Atlas common stock, have entered into a voting agreement in support of the transaction. The transaction is expected to close in Q2 of 2023.

12:00 EST Carvana falls -6.9% - Carvana is down -6.9%, or -69c to $9.31.

12:00 EST Annovis Bio rises 11.3% - Annovis Bio is up 11.3%, or $1.95 to $19.17.

12:00 EST C3.ai rises 25.2% - C3.ai is up 25.2%, or $4.10 to $20.40.

11:19 EST Pfizer says incremental share repurchases 'not high priority at this point' - Asked during the company's Q4 earnings call if the company can do more share buybacks given the current stock price, Pfizer CFO David Denton replied according to a transcript: "I think as we look at capital allocation at this point in time, we actually see a lot of opportunities to invest back into our business, both from a research perspective and importantly, getting behind our launches to make sure that we're doing all that we can to ensure that our growth trajectory in '25 and '30 and those goals and aspirations become reality. So I think our best and highest use of capital right now is investing in our business, both internally as well as from a BD [business development] perspective. I would say never say never to an incremental share repurchase, but that's not high on the priority list at this point."

11:03 EST Creative Realities reports $1.9M reduction in cash consideration obligations - Creative Realities announced that cash contingent consideration issuable in conjunction with its acquisition of Reflect Systems via merger in 2022 has been reduced by approximately $1.9M. The holders of Shares are entitled to receive, for each Share, a contingent cash payment on February 17, 2025 equal to the amount by which the average closing price of CRI common stock for the prior 15 trading days as reported on the Nasdaq Capital Market is less than $6.40 per share, or if certain conditions were met on or before December 31, 2022, less than $7.20 per share. CRI has determined that such conditions were not met on or before December 31, 2022. Accordingly, the continent cash payment amount has been reduced from $7.20 per Share to $6.40 per Share, a reduction of $0.80 per Share, or approximately $1.9M.

10:53 EST Edible Garden AG Inc trading resumes

10:43 EST Edible Garden AG Inc trading halted, volatility trading pause

10:00 EST Phillips 66 falls -4.8% - Phillips 66 is down -4.8%, or -$5.15 to $101.27.

10:00 EST BigBear.ai falls -15.7% - BigBear.ai is down -15.7%, or -62c to $3.35.

10:00 EST Annovis Bio rises 14.3% - Annovis Bio is up 14.3%, or $2.47 to $19.69.

09:57 EST Sysco: 'Strong' start to January volume performance - Says on target to grow more than 1.35x in FY23. Committed to "strong" investment grade rated balance sheet. Targeting net debt to adjusted EBITDA ratio of 2.50-2.75x. Comments taken from Q2 earnings conference call presentation slides.

09:47 EST Philips falls -5.2% - Philips is down -5.2%, or -94c to $17.05.

09:47 EST BigBear.ai falls -16.1% - BigBear.ai is down -16.1%, or -64c to $3.34.

09:47 EST Spotify rises 9.8% - Spotify is up 9.8%, or $9.84 to $109.84.

09:40 EST HubSpot announces restructuring plan, 7% workforce reduction - In a regulatory filing, the company announced that on January 25, the Board of Directors of HubSpot authorized a restructuring plan that is designed to reduce operating costs and enable investment in key opportunities for long-term growth while driving continued profitability. The Plan includes a reduction of the company's current workforce by approximately 7% and a lease consolidation to create higher density across its workspaces. The company estimates that it will incur charges of approximately $72M-$105M in connection with the Plan, consisting primarily of cash expenditures. $24M-$31M of the charges under the Plan are related to employee severance costs and $48M-$74M of the charges are related to lease consolidation. The actions associated with the workforce reduction under the Plan are expected to be substantially complete by the end of the first quarter of 2023, subject to local law and consultation requirements. The actions associated with the lease consolidation under the Plan are expected to be fully completed in 2023. The estimates of the charges and expenditures that the company expects to incur in connection with the Plan, and timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual amounts may differ from the estimates discussed above.

09:28 EST Nano Dimension issues special message to shareholders - Nano Dimension announced that publicly available information reveals hundreds of illegal actions by Murchinson and its manager, Marc Bistricer, including investigation by the U.S. authorities and the severe sanctions imposed on the Fund. The Company demands that the directors and managers at Murchinson report to Nano Dimension's shareholders about the sanctions imposed on them, and the circumstances that led to the investigation by the U.S. Securities and Exchange Commission, including an investigation against the leaders of the Fund and their enablers, led by Bistricer, who admitted to committing securities law violations and paid large fines of over $8 million. The Company will also combat the false smear campaign, which the Company believes to be led by Mr. Bistricer and the Fund against the management of Nano Dimension.

09:23 EST General Motors not contemplating big price increases this year

09:15 EST UHP provides update on FDA PMA application, White Lion agreement - United Health Products, UHP, provided an update on the company's FDA Premarket Approval, PMA, application process and the amendment of its Agreement with White Lion Capital. UHP continues to advance its Premarket Approval application with the Food and Drug Administration. Last December, a batch lot of HemoStyp gauze produced under its new manufacturing arrangements was shown to have physical and chemical characteristics that were effectively identical to those of the HemoStyp product utilized in the company's human trial. Subsequently, the company, in consultation with its regulatory consultant and reflecting feedback from the FDA, has produced additional batch lots of HemoStyp product to demonstrate consistent production, which the company believes is an important criterion for Premarket Approval. Samples of these additional lots are now undergoing similar laboratory testing procedures to confirm the consistency of the company's manufacturing process, which results will be included in its final PMA application. There can be no assurance that the company's PMA application will be approved. Separately, in September 2022 the company entered into a Common Stock Purchase Agreement with White Lion Capital, LLC under which the company has the right to sell shares of its common stock to White Lion at a price equal to 93% of the five-day volume weighted average trading price. The company has successfully raised over $350,000 to fund its operations under the Agreement. The Agreement contains a condition that the company share price must be above $0.25 per share in order to issue a share purchase notice, which White Lion can waive at its discretion. On January 25, 2023, the company and White Lion amended the Agreement such that if the company issues a purchase notice when its shares are trading below the Floor Price and White Lion waives the Floor Price condition, White Lion's purchase price per share in that transaction will be 90% of the five-day volume weighted average trading price rather than 93%. All other terms of the Agreement remain unchanged

09:13 EST Varonis announces proactive incident response for SaaS customers - Varonis Systems announced another milestone in its mission to deliver effortless data security outcomes with the launch of Proactive Incident Response. With this new offering, Varonis significantly reduces the pressure on customers' security operations teams and improves their ability to prevent data breaches. "IT and security teams face an uphill battle when it comes to identifying and acting on potential signs of a cyberattack - and the widening cybersecurity talent gap means companies can't hire their way out of this problem," says Matt Radolec, Senior Director, Incident Response and Cloud Operations, Varonis. "We have countless success stories from customers who have called on our incident response team to help investigate and contain threats. With the release of our cloud-hosted Data Security Platform, we can now proactively review our customers' alerts and stop threats faster."

09:12 EST Clearmind announces pre-clinical results treating MDD with novel compound - Clearmind Medicine announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial resulted in positive outcomes in relation to treating Major Depressive Disorder, MDD. The trial evaluated 2-Fluorodeschloroketamine's, an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its use in treating depression including treatment resistant depression. The purpose of this trial was to determine 2-FDCK's effect on the motivational state of rodents as a treatment for depressive behavior and to test 2-FDCK as a potential novel long-term pharmacological psychoactive treatment for MDD. In the trial, the Flinders Sensitive Line rat, an animal model of depression, were treated either by Ketamine or 2-FDCK for 14 consecutive days. The results indicated high potential safely treating both acute and chronic depression, compared to Ketamine that is used today for treating depression. The results suggest that there is a superior effect of 2-FDCK vs. Ketamine on the depressive-like behavior of the FSL animal model: Both Ketamine and 2-FDCK affected depressive-like symptoms. However, the effect was longer lasting when using a chronic treatment paradigm, only for 2-FDCK. "One of our goals of working closely with leading researchers around the world, is to investigate our proprietary compounds for new revolutionary treatments for addictions and mental health disorders. Our strong IP portfolio, includes numerous innovative compounds in the field of psychedelic-derived therapeutics," said Clearmind's CEO Dr. Adi Zuloff-Shani. "We are very encouraged by these preclinical data as we believe this could make a tremendous difference to patients suffering with treatment-resistant depression, who have limited options available to them."

09:08 EST General Motors sees 2023 revenue growth below 2022 levels

09:08 EST Motorsport Games regains full compliance with Nasdaq listing rules - Motorsport Games announced that it has received notice from the Nasdaq Stock Market on January 30, 2023 informing Motorsport Games that it has regained full compliance with the Nasdaq Listing Rules. Motorsport Games previously notified Nasdaq on November 11, 2022 that it was no longer in compliance with Nasdaq Listing Rule 5550(a)(4) requiring minimum of 500,000 publicly held shares.

09:07 EST AvidXchange names Dan Drees as President, Sutton as Chief Revenue Officer - AvidXchange announced that Dan Drees has been elevated to the role of President of AvidXchange. As the leader of sales, marketing, operations and product, Drees will be focused on driving organizational agility and greater operational synergies to advance the company's market leading position in AP and payments automation. Also announced, James Sutton joined AvidXchange as the Chief Revenue Officer, to lead both the Buyer and Supplier Customer sales functions. Drees has been with AvidXchange as Chief Growth Officer since 2018

09:05 EST Caterpillar: Pockets of supply chain challenges remain - Comments taken from Q4 earnings conference call.

09:02 EST Uber's Drizly, Gopuff announce partnership for on-demand delivery - Drizly, an Uber Company, and Gopuff announce a partnership to provide immediate, on-demand delivery of drinks to adults of legal drinking age. This new collaboration brings the full Gopuff Liquor & More assortment of beer, wine and spirits to Drizly's beverage alcohol e-commerce shop, while also expanding the number of BevMo! and Liquor Barn stores on the platform.

08:57 EST General Motors sees discounts on vehicles increasing this year

08:56 EST General Motors looks to inccrease inventory up to 60 days by year-end

08:50 EST Eaton Partners acts as exclusive placement agent for SKY Leasing Fund V - Eaton Partners announces that it has acted as exclusive placement agent for SKY Leasing and its Sky Fund V. SKY Leasing is a leading alternative asset manager with two decades of experience acquiring and selling new and young mid-life aircraft. The Fund closed oversubscribed with approximately $770M in capital commitments. SFV is a continuation of the investment program of SKY Leasing, focused on providing capital solutions to airlines seeking fleet modernization, primarily through the sale-leaseback of new aircraft deliveries. To date, SFV has committed over half of the capital raised to acquire a fleet of 48 aircraft with an average age under three years. "Thank you to Eaton Partners for the support we received for SFV," said Austin Wiley, Chief Executive Officer of SKY Leasing. "The Eaton team's strong network of institutional relationships helped broaden our investor base, which has enhanced our capabilities to provide large-scale fleet solutions to our global airline customer base."

08:49 EST Oatly Group introduces climate footprint labeling in North America - Oatly Group AB announced the introduction of climate footprint labeling for select Oatly products in North America, starting with the brand's newly reformulated line of Oatgurts - a range of great-tasting, non-dairy yogurt alternatives available in five delightful flavors. The effort to calculate climate footprints - intended to be the best estimate of the climate impact of a product - directly speaks to Oatly's belief that consumer choice and education plays an integral role in shaping the future of our food system.

08:48 EST Commvault to sell headquarters and lease back smaller footprint - The company expects the transaction to close in FY24 and sees proceeds of $40M. Comments from earnings conference call.

08:45 EST Iqvia teams with Alibaba for cloud commercial & clinical solutions in China - IQVIA (IQV) announces the first life sciences industry collaboration with Alibaba (BABA) Cloud in China. IQVIA and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, will be providing solutions hosted in Mainland China leveraging Salesforce on Alibaba Cloud. This will enable customers with a path to begin using or extending their investments on the best-in-class platform for engaging with their customers. "Through this new partnership between IQVIA and Alibaba Cloud, Salesforce life sciences customers will be able to better serve their customers, and patients, in China," said LaShonda Anderson-Williams, Executive Vice President & Chief Revenue Officer, Healthcare & Life Sciences. IQVIA will leverage its deep experience in developing life science technologies to provide customers with rich clinical to commercial products locally hosted on Alibaba's industry leading public cloud in China. This includes IQVIA's industry leading Orchestrated Customer Engagement suite of products for commercial customer engagement, designed to be compliant with Chinese data residency regulations.

08:43 EST General Motors to invest $650M in Lithium Americas to develop Thacker Pass mine - General Motors (GM) and Lithium Americas Corp. (LAC) announced they will jointly invest to develop the Thacker Pass mine in Nevada, which is the largest known source of lithium in the United States and the third largest in the world. Under the agreement, GM will make a $650M equity investment in Lithium Americas, which represents the largest-ever investment by an automaker to produce battery raw materials. Lithium Americas estimates the lithium extracted and processed from the project can support production of up to 1 million EVs per year. Lithium carbonate from Thacker Pass will be used in GM's proprietary Ultium battery cells. Lithium is a key material in lithium-ion batteries and stands up well to repeated charging and discharging (including enabling fast charging), delivers higher energy density, and offers more usable capacity than other battery types. GM is launching a broad portfolio of trucks, SUVs, luxury vehicles and light commercial vehicles using the Ultium Platform. GM's investment will be split between two tranches. The funds for the first tranche will be held in escrow until certain conditions are met, including the outcome of the record of decision ruling currently pending in U.S. District Court. If those conditions are met, the funds will be released and GM will become a shareholder in Lithium Americas. The escrow release is expected to occur no later than the end of 2023. The second tranche investment is expected to be made into Lithium Americas' U.S.-focused lithium business following the separation of its U.S. and Argentina businesses and is contingent on similar conditions, including Lithium Americas securing sufficient capital to fund the development expenditures to support Thacker Pass. Production at Thacker Pass is projected to begin in the second half of 2026. In connection with the closing of the first tranche investment, GM will receive exclusive access to Phase 1 production through a binding supply agreement and has the right of first offer on Phase 2 production. Lithium Americas expects Thacker Pass to create 1,000 jobs in construction and 500 in operations. GM has announced four U.S. cell plants with annual capacity of 160 gigawatt hours, including the Ultium Cells joint venture plant with LG Energy Solution in Warren, Ohio, which is in production, and additional JV sites in Spring Hill, Tennessee and Lansing, Michigan that are scheduled to open in 2023 and 2024, respectively. The first three Ultium Cells plants are expected to create 6,000 jobs in construction and 5,000 in operations. GM is currently building EVs in two Michigan plants, one Tennessee plant and one Ontario plant, and its suppliers are investing to create a robust North America-focused supply chain for EV raw materials, processed material and components, with major projects under way in California, Texas, Ohio and Quebec.

08:38 EST Griffon provides update on review of alternatives - The company said, "On May 16, 2022, Griffon announced that its Board of Directors initiated a process to review a comprehensive range of strategic alternatives to maximize shareholder value including a sale, merger, divestiture, recapitalization or other strategic transaction. While the process remains ongoing, there is no assurance that the process will result in any transaction being entered into or consummated."

08:37 EST Blue Star enter supply agreement for up to $4M annually with Just Food for Dogs - Blue Star Foods announces it has entered into an agreement with Just Food For Dogs. The initial contract for 2023 is expected to add an estimate of up to approximately $4 million annual revenue to Blue Star. Blue Star entered into a supply agreement for 1,150 tons or 2,500,000 lbs. of wild caught cod per year with Just Food For Dogs with an auto renewal option provision. The cod fishery is certified by MSC, Marine Stewardship Council, and is managed in a responsible and sustainable manner in accordance with internationally recognized criteria. John Keeler, Chairman and CEO of Blue Star Foods, commented, "We are thrilled to enter into this new relationship with Just Food For Dogs and expand into a new category for us, the pet/dog food industry. Our cod will be used as an ingredient used for their ala carte gourmet pet food." Trond Ringstad, Board Member commented, "You've got to visit a Just Food For Dogs store, as they are very impressive with their layout and selection of high quality dog food."

08:35 EST United Airlines, Green Plains form Joint Venture for ethanol aviation fuel - United Airlines (UAL), Tallgrass, and Green Plains (GPRE, GPP) announced a new joint venture - Blue Blade Energy - to develop and then commercialize a novel Sustainable Aviation Fuel - SAF - technology that uses ethanol as its feedstock. If the technology is successful, Blue Blade is expected to proceed with the construction of a pilot facility in 2024, followed by a full-scale facility that could begin commercial operations by 2028. SAF, which uses non-petroleum feedstock, is a low-carbon alternative to traditional jet fuel that offers up to 85% lower lifecycle greenhouse gas emissions. Tallgrass will manage research and development of the technology, including pilot plant development, and will manage the construction of the production facility. Green Plains will supply the low-carbon ethanol feedstock, and use its ethanol industry expertise to manage operations once the pilot facility is constructed. United Airlines will assist with SAF development, fuel certification and into-wing logistics, and has also agreed to purchase up to 2.7 billion gallons of SAF produced from the joint venture. Blue Blade Energy marks one of the largest direct investments from United Airlines Ventures, United's corporate venture arm, into SAF.

08:33 EST Commvault says delays and deferrals 'particularly acute' in December - Comments from Q3 earnings conference call.

08:21 EST Cerberus Sentinel announces strategic partnership with Kivu Consulting - Cerberus Cyber Sentinel Corporation announced a strategic partnership with Kivu Consulting to extend its service offerings in a number of areas, including incident response, digital forensics, ransomware negotiation, and proprietary cyber threat intelligence. In turn, Cerberus Sentinel will further extend Kivu's proactive cyber advisory services in North and South America. This agreement is the first of its kind for Cerberus Sentinel. "Cybersecurity is a team sport. With the massive workforce and talent gaps continuing to grow worldwide, a collaborative and coordinated approach is key. We are building a network of 'force multipliers' with the expertise, solutions, and services to combat today's advanced cyber threat actors and the attacks they perpetrate," said Ashley Devoto, president and CISO of Cerberus Sentinel. "Kivu is an excellent fit for a mutual partnership with Cerberus Sentinel. Both are known as trusted advisors as organizations continue to face a $2-trillion global cybersecurity challenge requiring innovation, battle-tested practitioners, and global scale to address cyber-attacks."

08:19 EST Sharps Technology ships first containers of safety syringes to Nephron - Sharps Technology announces the first shipments of product from its wholly owned manufacturing facility in Hungary to Nephron Pharmaceuticals to advance the Company's first commercial operations. Securegard is the first product that will be available to the market through the Company's collaboration with Nephron and will be introduced through Nephron's network of more than 3,000 customers. Robert Hayes, Sharps Technology CEO, commented: "With the first shipments of Securegard underway to Nephron, we mark the beginning of commercial operations for Sharps. We are committed to executing on our manufacturing and distribution plan and through this shipment, the Company will transition to revenue in the first half of 2023. Securegard will be the first of many innovative syringe systems that Sharps launches in collaboration with Nephron, and we look forward to announcing updates on new products from our portfolio this year."

08:18 EST ShockWave Medical announces coronary IVL included as treatment option by SCAI - Shockwave Medical announced that coronary IVL was included in a treatment guidance document published by the Society of Cardiovascular Angiography and Intervention, SCAI, as a potential therapeutic option in all U.S. catheterization labs. - including facilities without on-site surgical backup. The latest guidance - SCAI Expert Consensus Statement on PCI Without On-Site Surgical Backup - was published online in the Journal of the Society of Cardiovascular Angiography and Intervention, JSCAI. The updated guidelines, which modify the previous 2014 guidelines by no longer restricting recommended treatment to facilities with on-site surgical backup, will now endorse expanded treatment options and access for patients with calcified coronary lesions. The 2014 guidelines recommended avoiding treatment of high-risk lesions defined as "more than moderate calcification" in facilities without surgical backup. The updated guidelines note the old recommendation "restricted practice, limited patient choice and exposed interventional cardiologists to legal risk." "With the interventional field rapidly evolving, we commend SCAI for continuously evaluating current interventional practices to ensure that their consensus documents accurately provide the best possible guidance for optimal patient care," said Doug Godshall, Chief Executive Officer of Shockwave Medical. "We look forward to working with sites that have not yet adopted coronary IVL due to their lack of surgical backup and to expanding the number of centers that have access to our technology due to this new guidance."

08:17 EST DatChat hires Berrios as VP of Communications - DatChat announced the appointment of Christopher Berrios as Vice President, VP, of Communications for both Datchat's social media platform and the Habytat metaverse.

08:16 EST NetApp to reduce worldwide headcount by approximately 8% - In a regulatory filing, on January 31, announced a plan to restructure and reduce the company's workforce as a part of its planned efforts to realign resources to prioritize investments against its biggest opportunities in light of the macroeconomic challenges and reduced spending environment that continue to impact the company. In connection with these actions, the company expects to reduce its worldwide headcount by approximately 8%. The reduction in workforce is expected to be substantially implemented through the end of the fourth quarter of fiscal 2023. The company expects to incur aggregate charges of approximately $85M-$95M consisting primarily of employee severance and benefit costs associated with the restructuring. The company expects that most of these charges will be cash expenditures and that it will recognize the majority of these charges in the third quarter of fiscal 2023. The estimated charges that the company expects to incur are subject to a number of assumptions, and actual results may differ materially from these estimates. The company may also incur additional costs not currently contemplated due to unanticipated events that may occur as a result of, or that are associated with, its workforce reduction.

08:12 EST NV5 Global acquires Bromley Cook Engineering - NV5 Global announced that it has acquired Bromley Cook Engineering, a leading provider of forensics, specialty structural engineering, and waterproofing to support facilities and infrastructure throughout Florida. Headquartered in Fort Lauderdale, Bromley Cook's engineers and inspectors have worked on the design, renovation, and preservation of some of the state's most prestigious projects. The acquisition was made with a combination of cash and stock and will be immediately accretive to NV5's earnings. "Florida's wind, heat, humidity, and hurricane exposure create challenging conditions for the built environment, and facility owners rely on specialized structural engineering to design and preserve resilient buildings," said Dickerson Wright, PE, Chairman and CEO of NV5. "Bromley Cook's decades of experience in the Florida market make it uniquely qualified to identify construction defects, design durable structures, and deliver sustainable building solutions that will stand the test of time."

08:10 EST EDAP TMS announces results from Phase 2 study of HIFU - EDAP TMS announced positive clinical results from the Endo-HIFU-R1 Phase 2 study evaluating the safety of therapeutic high-Intensity focused ultrasound, HIFU, for the treatment of rectal endometriosis. Results from the study were presented by study coordinator, Pr. Gil Dubernard of Croix Rousse University Hospital, on Friday, January 27, at the Paris Sante Femmes French Congress. Endo-HIFU-R1 is a Phase 2 study designed to evaluate the safety of HIFU treatment of rectal endometriosis with EDAP's Focal One Robotic HIFU device. The study enrolled 60 patients across four centers in France between August 2020 and March 2022. Results from the study are based upon a six-month follow-up evaluation post-HIFU treatment. "These encouraging results validate the safety of Focal One HIFU treatment in this difficult and challenging endometriosis population," said Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS. "Positive data from the Endo-HIFU-R1 study represent an important milestone for EDAP and also underscore the potential of Focal One Robotic HIFU as a promising new treatment modality for patients suffering from this debilitating pathology. We would like to thank all of the patients and clinical investigators who participated in this important study. Based on these results, EDAP TMS intends to confirm the efficacy of Focal One HIFU treatment in rectal endometriosis by initiating a randomized, double-blind controlled study in the second quarter of 2023."

08:09 EST KemPharm announces two new additions to its senior management team - KemPharm announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs. Both positions are newly created at KemPharm and continue a series of enhancements to the Company's leadership to support its transformation into a leading rare disease company. Dr. Gallo joins KemPharm from Jaguar Gene Therapy. Maher joins KemPharm from Cytel.

08:08 EST Beam announce new ARC Mobility trailer for fast transport, relocation of EV ARC - Beam Global announced the ARC Mobility trailer, a specialized hydraulic transport solution designed to rapidly transport and relocate off-grid EV ARC sustainable EV charging systems. The transport system can be purchased to more efficiently manage the placement and movement of transportable Beam EV ARC solar-powered charging products. "Customers are building fleets of EV ARC charging systems. Our repeat customers are placing multi-unit second and third orders to build out their EV charging infrastructure with off-grid transportable EV ARC systems. We have also seen an increase in first-time customers placing multi-unit orders right out the gate," said Desmond Wheatley, Beam Global CEO. "The ability to easily relocate EV charging is a unique and valuable capability of the EV ARC systems, and with their own ARC Mobility trailer, customers can have ultimate flexibility for emergencies, power outages, events, moves from leased properties, or changes in emerging EV driver patterns. As EV charging demand, patterns and needs change, so can the emerging EV charging infrastructure."

08:06 EST Univar Solutions, Marott Graphic Services enter distribution pact in Europe - Univar Solutions B.V., a subsidiary of Univar Solutions, announced the company has been appointed as distributor for Marott Graphic Services unique rust protection additives for inks, coatings, rust prevention oils, and lubricants and metalworking fluids in Europe. The new agreement between the two companies includes additives for oils, lubricants, and coatings in the TINSCO range of rust inhibitors. Working together, Univar Solutions will offer customers access to an expansive range of additives for lubricants, metalworking fluids and rust prevention oils, while simultaneously providing MGS a reliable, technical-focused, and market leading distribution partner. Innovation is a top priority for both MGS and Univar Solutions as the two companies are bringing alternative solutions forward by focusing on sustainability in the lubricants and metalworking fluids and coatings space.

08:05 EST TransUnion announces investment in Bud to drive innovation, growth - TransUnion has announced a strategic investment in Bud Financial Limited. "This dynamic partnership will help drive innovation and growth in the personal finance market and support better outcomes for consumers, with greater financial inclusion," the company said. Open Banking allows finance providers to better verify the income of applicants, including those who may not have a detailed credit history, or have had trouble accessing credit previously, and offers an alternative to manual, often resource-intensive processes. "TransUnion is committed to increasing financial inclusion by continuing to expand the information available to create an accurate and reliable picture of each consumer," said Satrajit "Satty" Saha, CEO of TransUnion in the UK. "This strategic investment marks the start of an exciting new partnership with Bud, combining our global infrastructure and insights expertise with Bud's end-to-end Open Banking platform. This will allow us to grow our Open Banking offering and jointly develop the next generation of credit, affordability and fraud solutions."

08:05 EST Kymera Therapeutics and X-Chem a expand existing partnership - X-Chem announced the expansion of its collaboration with Kymera Therapeutics . With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library, DEL -based screening services to Kymera - with X-Chem applying its world-leading DEL platform to support Kymera's discovery of first- and best-in-class protein degraders. The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration. "Having worked with multiple DEL providers, we have been impressed with the quality of X-Chem's libraries and their scientific rigor," said Nello Mainolfi, Ph.D., Founder, President and CEO of Kymera Therapeutics. "Kymera's unique target selection strategy is critical to our success, and X-Chem has been a valued partner in helping us to unlock challenging disease targets that can be only or best addressed by targeted protein degradation. We look forward to extending our collaboration and working together to discover revolutionary new medicines."

08:04 EST Imperva appoints Eran Ben Ezer as CFO - Novidea appointed Eran Ben Ezer as CFO. Ezer has experience in fundraising, Initial Public Offerings, and M&A transactions. Before joining Novidea, Ezer served as the vice president of finance at Drivenets, a software company. Before Drivenets, Eran spent a decade as a financial executive at Imperva, where he held several roles and supported the company through its IPO.

08:03 EST Osisko files technical report on initial MRE for Tintic project - Osisko Development announces the filing of a technical report in relation to the initial mineral resource estimate, MRE, for the Company's 100%-owned underground Trixie deposit, within the Company's wider Tintic Project, located in central Utah, U.S.A. Highlights from the previously-announced Trixie MRE disclosed in the Company's news release dated January 17, 2023 are presented below, and are consistent with the Technical Report. The Technical Report, titled "NI 43-101 Technical Report, Initial Mineral Resource Estimate for the Trixie Deposit, Tintic Project, Utah, United States of America" and dated January 27, 2023, was prepared and compiled for the Company by independent representatives of Micon International Limited in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects.

07:56 EST Generac announces home standby generator integration with ecobee smart - Generac announced that its entire line of Wi-Fi and cellular-enabled home standby generators will soon integrate with the latest ecobee smart thermostats, creating a single energy management hub for the home. By integrating ecobee smart thermostats with Generac home standby generators, home energy management will be incorporated into a central, easy-to-use interface. Homeowners can quickly and easily see that their generator is ready to power on in a power outage. For homeowners fueling their generator with propane, they will also be able to digitally link their fuel tank, enabling them to monitor fuel levels 24/7 on the same interface.

07:50 EST ManpowerGroup CEO says Q4 results 'reflect a softening demand environment' - Jonas Prising, ManpowerGroup Chairman & CEO, said, "Our fourth quarter results reflect a softening demand environment, particularly in Europe and North America. We continue to invest resources into markets and brands where demand is strong and are exercising financial discipline where demand is slower. We remain focused on continuing to accelerate our strategic priorities and advancing our Diversification, Digitization and Innovation initiatives across our organization throughout 2023. I want to thank all of our talented teams for their continued energy, passion and resilience - helping our clients achieve their business outcomes while finding meaningful and fulfilling work for millions of people."

07:46 EST Tesla asked for documents on driver assist systems by DOJ - In a regulatory filing, Tesla said that the company has received requests from the DOJ for documents related to Tesla's Autopilot and FSD features. "To our knowledge no government agency in any ongoing investigation has concluded that any wrongdoing occurred. We cannot predict the outcome or impact of any ongoing matters. Should the government decide to pursue an enforcement action, there exists the possibility of a material adverse impact on our business, results of operation, prospects, cash flows and financial position."

07:44 EST GM expects to double company revenue to $275B-$315B by 2023 - Sees ~50% revenue CAGR in software and new businesses by 2030 while Cruise targets annual revenue of $50B by 2030. Sees core auto business target revenue CAGR of 4%-6% through 2030. Expects margin expansion to 12%-14% by 2030 with new businesses margins in excess of 20%.

07:42 EST NFI subsidiary receives launch order for 55 Enviro400EV buses from Stagecoach - NFI Group announced that transport group Stagecoach has placed the first order for the manufacturer's next-generation battery-electric buses, taking 55 Enviro400EV double-deck buses for its operation in Oxfordshire as part of the UK Government's Zero-Emission Bus Regional Areas, ZEBRA, scheme. Stagecoach is working with Oxfordshire County Council to decarbonize buses in and around Oxford thanks to funding from the UK Department of Transport as part of the Government's ZEBRA scheme. Britain's largest bus operator will introduce 55 electric Enviro400EV on its Oxford city and Oxfordshire networks from late 2023, becoming the first customer to place a firm order for the new battery-electric double decker fully designed and built by Alexander Dennis. "Our new Enviro400EV has been uncompromisingly designed to meet the requirements of bus operation in the UK, introducing latest advances in technology including our future-proof battery system while guaranteeing first-class aftermarket support throughout the vehicle's life with AD24," said Paul Davies, President & Managing Director, Alexander Dennis. "We are delighted to have our long-standing partner Stagecoach as the launch customer for Alexander Dennis' next generation of battery-electric buses, partnering with us to lead the future success of our bus and coach industry. This investment keeps funding from the Government's ZEBRA scheme in the UK, improving the lives of passengers and residents, and accelerating decarbonization."

07:40 EST Lilium joins forces with GKN Aerospace for Lilium Jet's EWIS - Lilium and GKN Aerospace have signed an agreement to work together to design and build an integrated and certifiable EWIS solution. From its facility in the Netherlands, GKN Aerospace will build the EWIS hardware sets and support Lilium with on-site installation into the Lilium Jet at Lilium's final assembly line at Oberpfaffenhofen, Germany. GKN Aerospace has a significant track record in the design and build of certifiable EWIS solutions within the aerospace industry. The scope of the collaboration covers the integrated design of the low voltage and high voltage electrical interconnections of the Lilium Jet. This includes: integration of all wire bundles in the Lilium Jet; integration of the electrical EWIS components into operational systems to safely fly the Lilium Jet; and development of innovative high voltage, high power interconnection solutions. Yves Yemsi, Chief Operating Officer at Lilium, said: "We're proud to have brought another outstanding aerospace player onto the Lilium Jet team. GKN Aerospace has enormous experience developing certifiable EWIS systems and impressed us with their dedicated offering for the Lilium Jet. We are looking forward to driving ahead on our program with GKN Aerospace at our side."

07:38 EST Reneo Pharmaceuticals receives fast track designation from FDA for REN001 - Reneo Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted mavodelpar, REN001, Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase, LCHAD, deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder, LC-FAOD. "Receiving this Fast Track designation for a second indication continues to solidify mavodelpar as a potential therapeutic option for patients with rare mitochondrial disease," said Gregory Flesher, President and Chief Executive Officer of Reneo Pharmaceuticals. "We appreciate the continued collaboration with the FDA and look forward to their partnership in advancing the LC-FAOD program which will include patients with LCHAD as well as other genotypes." The company recently completed a natural history study and an open label study evaluating mavodelpar in patients with LC-FAOD that included multiple genotypes, including the LCHAD genotype. Mavodelpar is also being evaluated in a pivotal clinical trial in patients with primary mitochondrial myopathies with mitochondrial DNA defects. The company expects topline data from the STRIDE study in the fourth quarter of this year.

07:36 EST PyroGenesis confirms receipt of milestone payment from Client B - PyroGenesis Canada confirms that, further to its press release dated January 26, 2023, it has received the project milestone payment of approximately $2.4M. This payment was triggered by the recently announced delivery of four 1-MW plasma torch systems to a major international iron ore producer, Client B, for use in the Client's iron ore pelletization furnaces - a key upstream part of the steelmaking process. As noted in the January 26th press release, the Client now has all major components related to the Company's plasma torch systems on site at one of their large, integrated iron ore mining and processing locations. This allows for the installation and trials to proceed at the Client's discretion, the conclusion of which is expected by the end of Q2 2023. The name of the Client - a multi-billion-dollar international producer of iron ore who is undertaking the testing of plasma torches to replace fossil fuel-burners as part of its iron ore pelletization process - has been kept confidential for competitive reasons.

07:32 EST Context announces Stemline received approval from U.S. FDA for ORSERDU - Context Therapeutics announced that its clinical trial collaborator, Stemline Therapeutics, a wholly owned subsidiary of The Menarini Group, received approval from the U.S. Food and Drug Administration, FDA, for ORSERDU for the treatment of postmenopausal women or adult men with estrogen receptor-positive, HER2-negative, Estrogen Receptor 1 gene-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. ORSERDU has shown improved efficacy over the current standard-of-care treatment, fulvestrant, in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. "This is a watershed moment for the industry, which has spent the last 20 years trying to develop a next-generation endocrine therapy that is pharmacologically superior to endocrine monotherapies, including fulvestrant. ORSERDU has the potential to fundamentally change the treatment paradigm for patients with ESR1-mutated breast cancer, which is found in approximately 40% of the estimated 43,500 patients with metastatic hormone-driven breast cancer in the United States," said Martin Lehr, CEO of Context Therapeutics. "Our collaboration with Menarini in the ongoing Phase 1b/2 ELONA trial is evaluating the potential of Context's oral progesterone receptor antagonist onapristone extended release, to enhance ORSERDU's activity in both ESR1-mutated and wild type metastatic breast cancer. Such a combination could potentially improve outcomes in patients without adding significant toxicity." ORSERDU is approved under the FDA's Priority Review and Fast Track designation based on the results of the registrational Phase III trial EMERALD, that demonstrated statistically significant progression-free survival with elacestrant vs SOC endocrine monotherapy, meeting both primary endpoints in all patients and in those patients whose tumors harbor ESR1 mutations.

07:21 EST Veritone sees a net $12M-$15M in annualized savings in FY23 - Ryan Steelberg, Veritone CEO, stated, "I am excited about 2023, the passionate focus on AI, and Veritone's leadership position in the market. Today, we are giving you insight into some of our strategic initiatives. As part of our actions, we are executing on three key areas of focus: (i) improving our balance sheet, which includes an increased focus on improving the profitability of our business, and our recent Q4 2022 debt repurchase, where we repurchased $60.0 million of our debt at 65% of par for a total cost of $39.0 million, (ii) reducing our cost structure to continue our mission and investment in our leading AI platform and applications, and (iii) deeper focus on near term product and solution initiatives and customer growth, continuing to expand and diversify our client base. I look forward to providing more details on these and other strategic actions during our next earnings call update in March 2023."

07:17 EST Hillstream BioPharma signs option agreement with Dana-Farber Cancer Institute - Hillstream BioPharma announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., certain of its proprietary technology which if converted to an exclusive license agreement, will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream's Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis. This approach combining HSB-1216 with conjugation to MUC1-C antibodies is highly synergistic for the elimination of CSCs, which is needed for long term responses and cures. "We look forward to this unique opportunity to work with Dr. Kufe and Dana-Farber," said Randy Milby, CEO of Hillstream. "This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients."

07:14 EST Greenidge Generation restructures $76M of secured debt with NYDIG - Greenidge Generation provided an update on the restructuring of its secured debt agreements with NYDIG and B. Riley, as well as the execution of hosting agreements with NYDIG affiliates and also announced selected preliminary financial and operating results for 4Q22. "The debt restructuring we've announced today significantly improves our balance sheet and provides us with a clear path forward as we enter 2023," said CEO Dave Anderson. "These agreements have effectively reduced our secured debt balances with these lenders from approximately $87M to approximately $26M and have the strong potential to allow us to further reduce our debt. We are actively working to secure and develop a new mining site, in partnership with NYDIG, which will reduce our debt by an additional $10M. We are also actively pursuing the sale of excess real estate at our site in Spartanburg, South Carolina, which is expected to reduce our debt with B. Riley by an additional $6 to $7M." Greenidge has restructured the secured debt with NYDIG of approximately $76M, including accrued interest, reducing it to approximately $17M, with the potential to reduce it to approximately $7M. Greenidge transferred miners to NYDIG with approximately 2.8 EH/s of mining capacity and will have approximately 1.1 EH/s of mining capacity remaining. Greenidge transferred certain credits and coupons to NYDIG. Further debt reduction of approximately $10M is possible, contingent upon Greenidge facilitating for NYDIG the rights to a mining site within three months. Greenidge is pursuing the sale of excess real estate that would be subdivided from the property housing its mining facility in South Carolina in order to apply such net proceeds to repay a portion of the Promissory Note.

07:11 EST Athira Pharma promotes Kevin Church to chief scientific officer - Athira Pharma announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer. "Kevin is a driving force behind our research at Athira. He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET pathway and its potential applications for the treatment of neurodegenerative disorders," said Mark Litton, Ph.D., President and CEO of Athira. "Kevin's leadership and dedication to exploring novel approaches is guided by an unwavering commitment to innovation and integrity that resonates not only within the research team but throughout the company." Dr. Church joined Athira in 2016 and most recently served as Executive Vice President, Research.

07:10 EST SilverCrest Metals reports Q4 operational results - Reports Q4 recovered metal, including inventory, of 11,940 oz. of gold and 1.20 million oz. of silver or 2.23 million oz. of silver equivalent. Q4 metal poured totaled 10,896 oz Au and 1.06 million oz Ag, or 2.01 million oz AgEq. Underground mining averaged 700 tons per day, below 2021 Feasibility Study forecast of 750 tpd, but in line with revised forecast of 600 to 700 tpd. At the end of 2022, the ore stockpiles were estimated at 261,600 tonnes below the 2021 Feasibility Study estimate of 311,200 tonnes due to a combination of higher processing rates and offset by lower mining rates than planned. Financial position with debt refinancing completed at a lower rate and a reduction of debt outstanding by $40.0M. Exited 2022 with $50.8M in cash and $50.0M in debt. COO Pierre Beaudoin remarked, "2022 was a pivotal year for SilverCrest with construction completed slightly ahead of schedule and under budget which is a rare achievement in this industry. This milestone set the positive tone for the ramp-up and declaration of commercial production in Q4, 2022. We are currently working on optimization of Las Chispas operations, and we expect to complete its Updated Technical Report in Q2, 2023 to provide the foundation for production and cost guidance going forward."

07:08 EST Kirby provides FY23 outlook, sees 'improved financial results' - Commenting on the 2023 full year outlook, David Grzebinski, Kirby's President and Chief Executive Officer, said, "We exited 2022 with solid strength in our businesses. The marine market remains healthy and we expect favorable market conditions in 2023. Our barge utilization is strong in both inland and coastal, and rates are steadily increasing. In distribution and services, despite persistent supply chain constraints and delays, demand for our products and services continues to grow, and we continue to receive new orders in manufacturing. Overall, we expect our businesses to deliver improved financial results in the coming quarters. While all of this is encouraging, we are mindful of economic challenges related to higher interest rates and a potential recession. Labor constraints and inflationary pressures appear to be moderating but continue to contribute to rising costs across our businesses. With these factors in mind, we will continue to focus on managing costs and driving cash flow from operations. In the near-term, we intend to use this cash flow to opportunistically return capital to shareholders and further strengthen our balance sheet. Also, consistent with our balanced approach to capital allocation, we will continue to evaluate accretive acquisitions and high-return organic growth opportunities to drive continued long-term shareholder value creation."

07:05 EST Shutterstock raises quarterly dividend 13% to 27c per share - Payable on March 16 to stockholders of record at the close of business on March 2.

07:03 EST LGI Homes announces expansion in Fort Myers market with newest community - LGI Homes announced the opening of a new community in the Fort Myers, Florida market, Arrowhead Reserve. LGI Homes at Arrowhead Reserve is situated between Fort Myers, Lehigh Acres, and Naples in the quaint town of Immokalee. LGI Homes at Arrowhead Reserve offers four floor plans ranging from 1,387 square feet to 1,984 square feet. Each new home includes a family room, 3 to 5 bedrooms, and 2 to 3 baths.

07:02 EST Whole Earth Brands launches Regenerative Organic Certified sugars - Whole Earth Brands will bring some of the first Regenerative Organic Certified sweeteners to market under its Wholesome brand. Wholesome has worked with Whole Foods Market to launch its Regenerative Organic Certified cane and turbinado sugars nationwide in the United States in January 2023. "We're very proud of this Wholesome launch, as the regenerative organic farming practices used to produce our Regenerative Organic Certified sugarcane at our partner farms in South America help restore the soil, capture carbon from the atmosphere and stay true to our Fair Wholesome Values," said Michael Franklin, Interim CEO, Whole Earth Brands. "As consumer education around regenerative organic farming increases, Wholesome Regenerative Organic Certified cane and turbinado sugars will provide an opportunity for consumers to vote for regenerative organic agriculture with their dollars. We are excited that Whole Foods Market is distributing our certified sugars to their national store footprint, which will expand awareness of the regenerative movement at large."

06:54 EST Victoria's Secret authorizes $125M accelerated share repurchase program - Victoria's Secret plans to enter into an accelerated share repurchase agreement with Goldman Sachs to repurchase $125N of the company's common stock. The company will make an initial payment of $125M to Goldman Sachs and will receive an initial delivery of approximately 2.5 million shares of the company's common stock on February 3. The final number of shares to be repurchased will be based on the volume-weighted average price of the company's common stock during the term of the ASR less a discount and subject to adjustments pursuant to the terms of the ASR. The final settlement of the ASR is expected to be completed in Q2. The planned ASR is a component of a broader share repurchase program authorizing the repurchase of up to $250M of the company's common stock.

06:52 EST Pfizer CFO says increasing investments behind launch products and pipeline - David Denton, CFO and Executive Vice President, stated: "I am very pleased with our fourth-quarter performance, which was highlighted by strong operational growth from Paxlovid, Prevnar 20, Comirnaty, Vyndaqel and Eliquis, as well as the inclusion of Nurtec ODT/Vydura and Oxbryta. For the full-year, we achieved revenues of over $100 billion, including 10 medicines or vaccines that generated revenues of more than $1 billion each, and all of this was accomplished despite operating in an environment in which foreign exchange reduced our revenues by 7%. Looking forward to 2023, we expect strong topline growth of 7% to 9% excluding our COVID-19 products and anticipated foreign exchange impacts. We are also increasing our investments behind our launch products and pipeline in order to help realize our growth goals for 2023 and beyond." Dr. Albert Bourla, Chairman and CEO, stated: "2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history, but more importantly, in terms of the percentage of patients who have a positive perception of Pfizer and the work we do. As proud as we are about what we have accomplished, our focus is always on what is next. As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we've ever had in such a short period of time. We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond."

06:49 EST Pfizer says FY23 guidance does not anticipate any share repurchases - As of January 31, 2023, Pfizer's remaining share repurchase authorization is $3.3B. Current financial guidance does not anticipate any share repurchases in 2023.

06:48 EST Pfizer provides FY23 revenue guidance for COVID-19 products - Revenue guidance for Pfizer's COVID-19 products is as follows: Comirnaty revenues of approximately $13.5B, down 64% from actual 2022 results. Paxlovid revenues of approximately $8B, down 58% from actual 2022 results. In contrast to previous years, guidance for both products is no longer based primarily on expected deliveries under existing signed or committed supply contracts, but now also includes, among other things, anticipated sales through traditional commercial markets in the U.S. in the second half of 2023.

06:37 EST Karuna Therapeutics appoints William Kane as Chief Commercial Officer - Karuna Therapeutics appointed Will Kane as chief commercial officer, effective February 6. Kane has held senior level commercial positions at biopharma companies Allergan, Pfizer, and Sepracor, and was an integral part of launching several brands. Most recently, he was the executive vice president and chief commercial officer at BioXcel Therapeutics.

06:35 EST Exxon Mobil reports Q4 cash flow from operating activities $18.95B - Reports Q4 free cash flow $12.27B

06:18 EST UBS: Starting 2023 from a position of strength - CEO Ralph Hamers said: "We are starting 2023 from a position of strength. While the macroeconomic outlook remains uncertain, our operational resilience, capital strength and capital generation put us in a great position to serve our clients, fund growth and deliver strong capital returns to shareholders. We remain committed to a progressive dividend and expect to repurchase more than USD 5bn of shares in 2023."

06:12 EST UPS reports Q4 adjusted consolidated operating margin of 14.1%

06:09 EST Amazon.com grows renewable energy capacity by 8.3 gigawatts in 2022 - Amazon announced that in 2022 it grew its renewable energy capacity by 8.3 gigawatts through 133 new projects in 11 countries. This brings Amazon's total portfolio to more than 20 GW-that could generate the amount of energy to power 5.3M U.S. homes-across 401 renewable energy projects in 22 countries. The company's renewable energy purchases continue to add new wind and solar projects on the grids that power Amazon's operations, including Amazon Web Services data centers, Amazon fulfillment centers, and physical stores around the world. With these continued investments, Amazon set a new corporate record for the most renewable energy announced by a single company in one year. The company remains the largest corporate buyer of renewable energy-a position it's held since 2020, according to Bloomberg New Energy Finance. Amazon's continued investment in renewable energy helps to accelerate growth in new regions through innovative deal structures, technologies, and cloud solutions. These purchases also bring Amazon closer to powering its operations with 100% renewable energy by 2025-five years ahead of its original 2030 target. In 2022, the company announced new projects in Australia, Canada, Finland, France, Germany, Japan, Poland, Singapore, Spain, and the U.S., and broke ground in Brazil, India, and Indonesia. With 25 new renewable energy projects secured to close out the year, the company now has 401 projects globally, including 164 wind farms and solar farms, and 237 rooftop solar projects on Amazon facilities. Once operational, Amazon's global renewable energy projects are expected to generate 56,881 gigawatt-hours of clean energy each year.

06:07 EST M.D.C. Holdings sees Q1 home deliveries 1,500-1,600 - Sees Q1 average selling price $550,000-$560,000. Sees Q1 gross margin 18%-19%.

06:05 EST Dole sells Fresh Vegetables Division to Fresh Express for $293M in cash - Dole announced that certain of its subsidiaries have entered into a definitive agreement to sell Dole's Fresh Vegetables Division to an affiliate of Fresh Express, a wholly owned subsidiary of Chiquita Holdings, for gross proceeds of approximately $293M in cash, subject to certain adjustments. The Fresh Vegetables Division comprises operations related to the processing and sale of whole produce such as iceberg, romaine, leaf lettuces, cauliflower, broccoli, celery, asparagus, artichokes, green onions, sprouts, radishes, and cabbage, as well as salads and meal kits. In the financial year ended December 31, 2021, the Fresh Vegetables Division reported revenue of $1.28B. The business has agricultural operations and four processing plants across the United States and employs more than 3,000 people. The transaction is subject to regulatory approval and the parties expect that the transaction will close after approval is obtained, subject to customary closing conditions. Net proceeds from the sale are currently expected to be used primarily for debt reduction of Dole.

06:03 EST UPS sees FY23 CapEx about $5.3B - The company is planning capital expenditures to be about $5.3B, dividend payments to be around $5.4B, subject to board approval, and share repurchases to be around $3B. The effective tax rate is expected to be around 23.5%. Sees FY23 consolidated adjusted operating margin of between 12.8% and 13.6%.

06:01 EST UPS raises quarterly dividend 6.6% to $1.62 per share - For the 14th consecutive year, the UPS Board of Directors has approved an increase to the company's quarterly dividend. UPS will pay a first-quarter 2023 dividend of $1.62 per share on all outstanding Class A and Class B shares. The dividend is payable March 10 to shareowners of record on February 21.

05:34 EST Standard Lithium installs Carbon Capture Pilot Plant in Arkansas - Standard Lithium announced that its Carbon Capture Pilot Plant has been successfully installed at the final testing location in southern Arkansas. The Carbon Capture Pilot Plant will assess the technical and financial viability of capturing CO2 directly from natural gas burning flue-gas streams, and will inform how Standard Lithium can use technology to minimize CO2 emissions at future production facilities.

05:27 EST Barrick Gold makes initial $3M payment to Balochistan government for Reko Diq - Barrick Gold has paid the first $3M to the Balochistan provincial government as part of the new Reko Diq partnership. After the signing of definitive agreements and completion of legal process last month, Barrick and the Government of Balochistan recently agreed upon the timetable for the disbursement of committed funds to the province. Reko Diq Pakistan Country Manager Ali E. Rind handed over the check for $3M to Secretary, Mines and Minerals Development Department, Saidal Khan Luni. The new Reko Diq agreement ensures that benefits from the project start accruing to the people of Balochistan well before the mine goes into production through advance royalties and social development funds. During peak construction the project is expected to employ approximately 7,500 people and once in production it will create around 4,000 long-term jobs. Barrick's policy of prioritizing local employment and suppliers will have a positive impact on the local economy. Barrick is working to set up community development committees to identify priority projects focused on food security, environmental management and access to education, healthcare and potable water. The company plans to finish the Reko Diq feasibility study update by the end of 2024, with 2028 targeted for first production.

05:21 EST Dada Nexus, JD.com announce results from JD Shop Now Spring Festival - JD Shop Now released the "2023 Report of on-demand Consumption in Spring Festival." During the Chinese Spring Festival, JD Shop Now sales have increased by 90% compared to the Spring Festival last year. The search volume for Spring Festival decorations such as couplets, lucky characters, and red paper cuttings rapidly increased, more than 3.5 times that of the same festive period last year. Data from JD Shop Now shows that gift boxes, fruits, alcoholic beverages, and mobile phones are the most popular during the Spring Festival. On New Year Eve, the consumer's order amount increased by 171% year-on-year. Data from JD Shop Now shows that during the Chinese New Year period, sales of mobile phones increased by more than 70% compared to the previous year, cosmetics and perfume sales increased by more than 120%, sales of home appliances increased by 226%.Sales of smart health monitoring products on JD Shop Now increased by more than 10 times, and sales of massagers, electric health pots, and air purifiers increased by more than 2 times. The data shows that the sales of kitchen appliances such as floor-cleaning robots, cooking machines, and air fryers experienced explosive growth, and increased by more than 8 times compared to the previous year. In October 2021, Dada Group (DADA) and JD.com (JD) jointly launched the Shop Now service.